2,884 Shares in Spark Therapeutics Inc (ONCE) Purchased by Commonwealth Equity Services Inc

Commonwealth Equity Services Inc purchased a new stake in shares of Spark Therapeutics Inc (NASDAQ:ONCE) during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 2,884 shares of the biotechnology company’s stock, valued at approximately $257,000.

Several other hedge funds have also made changes to their positions in ONCE. Teachers Advisors LLC lifted its stake in shares of Spark Therapeutics by 1.9% during the 1st quarter. Teachers Advisors LLC now owns 34,534 shares of the biotechnology company’s stock valued at $1,842,000 after buying an additional 650 shares in the last quarter. Schwab Charles Investment Management Inc. lifted its stake in shares of Spark Therapeutics by 9.5% during the 1st quarter. Schwab Charles Investment Management Inc. now owns 87,751 shares of the biotechnology company’s stock valued at $4,681,000 after buying an additional 7,605 shares in the last quarter. Credit Suisse AG lifted its stake in shares of Spark Therapeutics by 96.7% during the 1st quarter. Credit Suisse AG now owns 46,174 shares of the biotechnology company’s stock valued at $2,463,000 after buying an additional 22,697 shares in the last quarter. Russell Investments Group Ltd. lifted its stake in shares of Spark Therapeutics by 81.6% during the 2nd quarter. Russell Investments Group Ltd. now owns 25,228 shares of the biotechnology company’s stock valued at $1,507,000 after buying an additional 11,335 shares in the last quarter. Finally, C WorldWide Group Holding A S lifted its stake in shares of Spark Therapeutics by 16.6% during the 2nd quarter. C WorldWide Group Holding A S now owns 52,281 shares of the biotechnology company’s stock valued at $3,123,000 after buying an additional 7,449 shares in the last quarter. Institutional investors own 94.94% of the company’s stock.

A number of analysts recently commented on ONCE shares. Chardan Capital upgraded shares of Spark Therapeutics from a “neutral” rating to a “buy” rating and upped their price target for the company from $60.00 to $100.00 in a research note on Tuesday, August 8th. Evercore ISI started coverage on shares of Spark Therapeutics in a research note on Wednesday, August 16th. They set an “in-line” rating and a $83.00 price target on the stock. Cantor Fitzgerald restated a “buy” rating on shares of Spark Therapeutics in a research note on Friday, August 25th. BidaskClub upgraded shares of Spark Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, August 26th. Finally, Barclays started coverage on shares of Spark Therapeutics in a research note on Wednesday, September 6th. They set an “overweight” rating and a $104.00 price target on the stock. Three equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and eighteen have given a buy rating to the stock. Spark Therapeutics currently has an average rating of “Buy” and a consensus target price of $90.36.

In other news, insider Katherine A. High sold 5,000 shares of the stock in a transaction on Tuesday, November 28th. The shares were sold at an average price of $71.32, for a total value of $356,600.00. Following the transaction, the insider now owns 215,000 shares of the company’s stock, valued at approximately $15,333,800. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider Daniel Faga sold 3,000 shares of the stock in a transaction on Thursday, September 7th. The stock was sold at an average price of $85.02, for a total transaction of $255,060.00. Following the completion of the transaction, the insider now directly owns 3,000 shares in the company, valued at approximately $255,060. The disclosure for this sale can be found here. Insiders have sold a total of 1,083,309 shares of company stock worth $91,004,945 in the last ninety days. 7.30% of the stock is currently owned by insiders.

Shares of Spark Therapeutics Inc (NASDAQ:ONCE) opened at $70.08 on Monday. Spark Therapeutics Inc has a twelve month low of $47.03 and a twelve month high of $91.75.

Spark Therapeutics (NASDAQ:ONCE) last posted its earnings results on Tuesday, November 7th. The biotechnology company reported ($1.90) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.79) by ($0.11). The firm had revenue of $1.90 million for the quarter, compared to the consensus estimate of $1.40 million. Spark Therapeutics had a negative return on equity of 60.01% and a negative net margin of 1,090.11%. The business’s revenue was up 45.8% on a year-over-year basis. During the same period last year, the company posted ($1.07) EPS. equities research analysts anticipate that Spark Therapeutics Inc will post -7.6 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: This piece was originally published by Community Financial News and is the property of of Community Financial News. If you are reading this piece on another publication, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The correct version of this piece can be viewed at https://www.com-unik.info/2017/12/04/2884-shares-in-spark-therapeutics-inc-once-purchased-by-commonwealth-equity-services-inc.html.

Spark Therapeutics Company Profile

Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.

Institutional Ownership by Quarter for Spark Therapeutics (NASDAQ:ONCE)

What are top analysts saying about Spark Therapeutics Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Spark Therapeutics Inc and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit